Gene therapy company Lexeo Therapeutics nabs $100m Series B

Lexeo Therapeutics, a clinical-stage gene therapy company, has secured $100 million in Series B financing.

Lexeo Therapeutics, a clinical-stage gene therapy company, has secured $100 million in Series B financing. D1 Capital Partners and Eventide Asset Management led the round with participation from CAM Capital, Verition Fund Management, Laurion Capital Management, Gray’s Creek Capital Partners, Longitude Capital, Omega Funds, Lundbeckfonden Ventures, PBM Capital, Janus Henderson Investors, Woodline Partners LP, Invus Capital and Alexandria Venture Investments.

Source: Press Release